Subventions financées

The increasing prevalence of anxio-depressive disorders worldwide suggests that current therapeutic strategies are insufficient in tackling this global health concern.

The Challenge: Current therapies for treating a number of mental health disorders – depression, anxiety,
and PTSD, among them – adequately treat only a small fraction of afflicted patients.

“Vascular pathology, such as loss of neurovascular coupling and disruption of the blood-brain barrier (BBB), has been documented in Huntington’s disease (HD).

Psychedelic drugs, known for their profound effects on perception, are showing promise as rapid and long-lasting treatments for depression.

“Research evidence identifies that people from equity-seeking groups, particularly those from racialized communities face significant barriers along their dementia journey, both from an individual (community) and a system (policy) perspective.

The fight against ALS is made extremely challenging due to its largely unknown origin in most patients.

Genetic testing shows that the Tau gene can often carry changes (DNA mutations) in people with dementia, and also in people who are not yet diagnosed with dementia.

Deregulation of brain cell metabolism is commonly observed in low-grade brain cancers.

Periodontal disease has links with Alzheimer’s disease.

In Canada, about 1.1 million people care for family members with dementia, providing support that saves the healthcare system billions each year.